Orthocell Accelerates Global Expansion for Remplir, Shares Rally 14%

MT Newswires Live
01-22

Orthocell (ASX:OCC) is set to accelerate its plans to enter several key markets in 2025, with a regulatory submission for its Remplir product for Canada expected to be lodged shortly, on the back of a third consecutive quarter of record revenue, according to a Wednesday Australian bourse filing.

It plans to submit regulatory applications for the peripheral nerve reconstruction product in Thailand during the March quarter, in the European Union and UK during the September quarter, and in Brazil during the December quarter.

The firm had earlier submitted its US regulatory application for clearance to commercially distribute Remplir, with approval expected in either March or April. Remplir is currently approved for sale in Australia, New Zealand, and Singapore.

It said that it is progressing with preparations for its US market launch, including the recruitment of an initial sales team and distributor appointments.

The firm's shares rallied 14% in early trading on Wednesday.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10